Skip to Content

IDEXX Laboratories Inc

IDXX: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$329.00MvtkdgVphrvnctrp

Idexx Earnings: Solid Volume and Price Gains Propelled Robust Result

Narrow-moat Idexx Labs posted fourth-quarter and full-year results that were generally consistent with our top and bottom line estimates, and our projections for 2024 remain within the bounds of management’s outlook. Though we haven’t altered our modeling assumptions, we do expect to modestly raise our fair value estimate to reflect the cash flow realized since our last update. Nevertheless, shares remain overvalued from our perspective.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of IDXX so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center